Aakaar Medical Technologies Ltd
Aakaar Medical Technologies Q4 FY26 earnings call: Revenue & Margins
Q4 FY26 earnings call: what management guided on revenue, margins and order book.
What the Q4 FY26 call signalled
1 of 3 strong
The short version
Targeting a CAGR of 30% going forward to maintain strong growth. Management targets a CAGR of 30% and above for revenue growth going forward.
From Aakaar Medical Technologies Ltd's Q4 FY26 earnings-call transcript · updated 23 Aug 2026.
Revenue & Sales Performance
- Targeting a CAGR of 30% going forward to maintain strong growth.
- New brands like Letybo, Xomage, and VM Portfolio expected to significantly boost top line.
- Focus on growing top 10 brands, currently contributing 65-67% of revenue.
- Expansion plans include increasing presence in hair transplant and consumables markets.
- Xelix clinic platform to drive growth by integrating marketing and expanding doctor participation.
- Hair care category with proprietary products like DRS1512 has potential to reach several hundred crores in revenue.
- Expected growth driven by stabilized portfolio, launch of new products, and USFDA-approved filler.
2 more points from Aakaar Medical Technologies Ltd's call on revenue
Pro opens every point from 15K+ earnings calls
Profitability & Margins
See what Aakaar Medical Technologies Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Currently, there is no major CAPEX planned for clinic expansion as the Xelix clinic model is doctor-operated with no direct CAPEX from Aakaar; clinics are tied up under the Xelix platform without ownership by the company.
- Future plans may involve taking franchise fees from new doctors in the Xelix platform, indicating potential strategic investment in scaling this platform.
- Investment is underway in manufacturing and developing an exclusive hair transplant device, aiming for patenting and improving transplant success rates, which is an early-stage strategic capital commitment.
2 more points from Aakaar Medical Technologies Ltd's call on capex
Pro opens every point from 15K+ earnings calls
Top-ranked in Personal Products
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Aakaar Medical Technologies Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
2 more points from Aakaar Medical Technologies Ltd's call on order book
Pro opens every point from 15K+ earnings calls
Continue your research
What Aakaar Medical's management said in earlier quarters
Others in Personal Products this season
- Anondita Medicare Ltd (Q4 FY26)
Current unexecuted order book stands at approximately INR137 crores, which remains intact from the previous year. Key concall takeaways from Anondita Medicare…
- Cupid Ltd (Q4 FY26)
Q4 FY26 Revenue from operations: ₹119.96 Cr, up 112.39% YoY from ₹56.48 Cr in Q4 FY25 (Page 18). Key concall takeaways from Cupid Ltd's Q4 FY26 earnings call…
- Honasa Consumer Ltd (Q4 FY26)
Increasing contribution from focus categories, which grew 35% year-on-year and now receive over 90% of investments. Key concall takeaways from Honasa Consumer…
- Bajaj Consumer (Q4 FY26)
Revenue growth momentum is strong, with a 21% increase for the full year FY26 and a 30% top-line growth noted in Q4. Key concall takeaways from Bajaj Consumer…
Arthneeti Pro · Annual
Aakaar Medical Technologies Ltd and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Aakaar Medical Technologies Ltd Q4 FY26 results?
Targeting a CAGR of 30% going forward to maintain strong growth. Management targets a CAGR of 30% and above for revenue growth going forward.
What is Aakaar Medical Technologies Ltd share price analysis?
Aakaar Medical Technologies Ltd currently shows a moderate growth signal based on ranking data. The stock trades at a P/E of 14.3 with a market cap of ₹95 Cr. Investors should review the full earnings analysis for detailed insights.
Is Aakaar Medical Technologies Ltd planning capital expenditure?
Currently, there is no major CAPEX planned for clinic expansion as the Xelix clinic model is doctor-operated with no direct CAPEX from Aakaar; clinics are tied up under the Xelix platform without ownership by the company.
Keep Aakaar Medical Technologies Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.